BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission.
October 13, 2021
by prnasia
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study...
September 28, 2021
by prnasia
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320...
September 23, 2021
by prnasia
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
BioVaxys Technology Corp. is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development ...
August 4, 2021
by prnasia
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
BioVaxys is pleased to announce that the US Food and Drug Administration has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.
July 23, 2021
by prnasia
BioVaxys Announces Non-Brokered Private Placement
BioVaxys Technology Corp. is pleased to announce a non-brokered private placement consisting of up to 9,090,909 units at a price of $0.22 per Unit for total gross proceeds of up to approximately $2,000,000.
June 29, 2021
by prnasia
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development
BioVaxys Technology Corp. is pleased to announce today that FDA has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has determined that a Written Response is sufficient to address the Company's questions regarding
June 15, 2021
by prnewswire
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study
BioVaxys Technology Corp. is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated construction of a new Good Manufacturing Practice clean room facility needed for producing clinical supply of BVX-0918A ...
June 2, 2021
by prnasia
BioVaxys Announces Appointment of Policy Advisor
BioVaxys Technology Corp., a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, announced the appointment of Adam Coutts, PhD, as Policy Advisor.
May 21, 2021
by prnasia
BioVaxys Inks Deal with CDMO BioElpida
BioVaxys Technology Corp. has signed a definitive exclusive bioproduction agreement with BioElpida S.A.S. of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys' vaccine candidate for Stage III/Stage ...
May 6, 2021
by contractpharma
Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day
BioVaxys Technology Corp., the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship of this year's World Ovarian Cancer Day, a major initiative of the World Ovarian Cancer Coalition, an ...
April 21, 2021
by prnasia
BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology
BioVaxys Technology Corp., the world leader in haptenized antigen vaccines for antiviral and cancers applications, is pleased to announce the results of a clinical study conducted by ProCare Health Iberia, its EU partner for marketing its ...
April 15, 2021
by prnasia